$26.30
0.48[1.86%]
Last update: 1:57PM Get Real Time Here
Latest News for XOMA Stock (NASDAQ:XOMA)
XOMA Stock (NASDAQ: XOMA)
Categories: All
Monday, March 11, 2024
Friday, March 08, 2024
Friday, February 16, 2024
- HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price TargetBenzinga Newsdesk - Feb 16, 2024, 1:41PM
- Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate BiopharmaVandana Singh - Feb 16, 2024, 12:55PM
- XOMA Enters Agreement To Acquire Kinnate Biopharma For Between $2.3352 And $2.5879 In Cash Per Share Plus A Contingent Value RightBenzinga Newsdesk - Feb 16, 2024, 8:02AM
- Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Feb 16, 2024, 7:55AM
Thursday, January 18, 2024
- Talphera Announces $26M Capital Commitment Through A Combination Of A Non-Dilutive Royalty Monetization And Equity OfferingBenzinga Newsdesk - Jan 18, 2024, 8:35AM
- XOMA Expands Its Commercial Royalty And Milestone Portfolio With DSUVIA Acquisition; Provided An $8M Non-Dilutive Royalty Capital Solution To TalpheraBenzinga Newsdesk - Jan 18, 2024, 8:32AM
Thursday, January 11, 2024
Monday, January 08, 2024
Tuesday, January 02, 2024
Friday, December 22, 2023
Tuesday, November 07, 2023
Tuesday, October 31, 2023
Wednesday, October 04, 2023
Wednesday, September 13, 2023
Monday, September 11, 2023
Friday, September 01, 2023
Monday, August 28, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
Thursday, July 27, 2023
Wednesday, July 26, 2023
Thursday, June 22, 2023
- Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: AnalystVandana Singh - Jun 22, 2023, 3:09PM
- HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $69 Price TargetBenzinga Newsdesk - Jun 22, 2023, 10:48AM
- Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, RespectivelyBenzinga Newsdesk - Jun 22, 2023, 7:39AM
Thursday, June 15, 2023
Wednesday, May 24, 2023
Tuesday, May 09, 2023
Thursday, March 30, 2023
- Aptevo Therapeutics Says Has Raised $9.6M In Non-Dilutive Funding By Closing Transaction For Sale Of All Future IXINITY Deferred Payments And A Portin Of IXINITY Milestones To XOMABill Haddad - Mar 30, 2023, 7:35AM
- XOMA Acquires Full Commercial Payment Stream And a Portion Of Aptevo's Milestone Rights Related To IXINITY For $9.6MBill Haddad - Mar 30, 2023, 7:32AM